Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Beta 2 microglobulin in multiple myeloma.

R Alexanian, B Barlogie, H Fritsche

    American Journal of Hematology
    |December 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma.

    Leukemia·2018
    Same author

    Drug response prediction in high-risk multiple myeloma.

    Gene·2017
    Same author

    Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing.

    Nature communications·2017
    Same author

    Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma.

    Leukemia·2017
    Same author

    NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma.

    Leukemia·2017
    Same author

    Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker.

    Blood cancer journal·2017
    Same journal

    High Proportion of PNH Type II Neutrophils Is Associated With Thrombosis in Patients Displaying a PNH Clone ≥ 1.

    American journal of hematology·2026
    Same journal

    Peripheral Blood Lymphocytosis Reflecting an Underlying Thymoma.

    American journal of hematology·2026
    Same journal

    Undetectable Hydroxyurea Levels in the Majority of Sickle Cell Disease Patients, Especially in Young Children.

    American journal of hematology·2026
    Same journal

    Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk-Stratification and Management.

    American journal of hematology·2026
    Same journal

    Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.

    American journal of hematology·2026
    Same journal

    Comparative Efficacy of Intranasal, Intramuscular, and Intravenous Vitamin B12 Therapy for Hematological Recovery in Vitamin B12 Deficiency Anemia: A Randomized Controlled Trial.

    American journal of hematology·2026
    See all related articles

    Serum beta 2 microglobulin (B2M) levels help assess multiple myeloma tumor burden and treatment response. Elevated pretreatment B2M indicates a poorer prognosis and shorter survival time in these patients.

    Area of Science:

    • Oncology
    • Clinical Chemistry

    Background:

    • Multiple myeloma is a hematologic malignancy characterized by uncontrolled plasma cell proliferation.
    • Accurate assessment of tumor burden and treatment efficacy is crucial for patient management.

    Purpose of the Study:

    • To evaluate the utility of serum beta 2 microglobulin (B2M) levels in previously untreated multiple myeloma patients.
    • To correlate B2M levels with tumor mass, chemotherapy response, and survival outcomes.

    Main Methods:

    • Serum B2M levels were measured in 97 untreated multiple myeloma patients before and during chemotherapy.
    • B2M values were analyzed in relation to tumor mass grade, remission status, and survival.
    • The impact of correcting B2M for serum creatinine was also assessed.

    Related Experiment Videos

    Main Results:

    • Pretreatment B2M levels effectively indicated tumor mass grade.
    • Significant reductions in B2M post-chemotherapy correlated with achieving remission.
    • A pretreatment B2M level exceeding 6 mg/L was associated with a low response rate.
    • High pretreatment B2M was the most significant predictor of a short survival time.

    Conclusions:

    • Serum B2M is a valuable biomarker in multiple myeloma for assessing tumor burden and predicting treatment outcomes.
    • Elevated pretreatment B2M levels are indicative of a poor prognosis and reduced survival.
    • Monitoring B2M levels during chemotherapy aids in evaluating treatment response and remission status.